TerrAscend (TSNDF) Net Income towards Common Stockholders (2021 - 2026)

TerrAscend's (TSNDF) quarterly Net Income towards Common Stockholders came in at -$1.2 million in Q1 2026, up 74.48% year-on-year from -$673434.6 in Q1 2025, and down 128.59% on a QoQ basis from $4.1 million in Q4 2025.

TerrAscend (TSNDF) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends

TerrAscend (TSNDF) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$1.2 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 74.48% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$53.4 million, a 5.3% decrease from a year earlier, with the FY2025 full-year figure at -$56.8 million, down 9.78% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$1.2 million, down from $4.1 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for TSNDF reached as high as $4.1 million in Q4 2025 and fell as low as -$54.7 million in Q4 2023.
  • Historically, Net Income towards Common Stockholders has averaged -$12.0 million across 5 years, with a median of -$4.6 million in 2025.
  • On a YoY basis, Net Income towards Common Stockholders climbed as much as 110.13% in 2025 and fell as far as 86977.08% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$10.6 million in 2022, then plunged by 417.02% to -$54.7 million in 2023, then climbed by 25.74% to -$40.6 million in 2024, then soared by 110.13% to $4.1 million in 2025, then plunged by 128.59% to -$1.2 million in 2026.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$1.2 million in Q1 2026, $4.1 million in Q4 2025, and -$14.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 90.13 Bn 88.27 Bn - -
2 Teva Pharmaceutical Industries 35.98 Bn 32.24 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.59 Bn 30.65 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.55 Bn 23.49 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 23.08 Bn 20.93 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 21.48 Bn 21.48 Bn - -
7 Viatris 20.38 Bn 18.57 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.80 Bn 16.48 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.64 Bn 12.21 Bn 785.00 Mn 57.00 Mn
10 TerrAscend 168.49 Mn 168.02 Mn 34.60 Mn -1.18 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.18 Mn
Dec 31, 2025 4.11 Mn
Sep 30, 2025 -14.65 Mn
Jun 30, 2025 -41.70 Mn
Mar 31, 2025 -4.60 Mn
Dec 31, 2024 -40.59 Mn
Sep 30, 2024 -5.58 Mn
Jun 30, 2024 48,000.00
Mar 31, 2024 -14.85 Mn
Dec 31, 2023 -54.66 Mn
Sep 30, 2023 -232,000.00
Jun 30, 2023 -621,000.00
Mar 31, 2023 -3.59 Mn
Dec 31, 2022 -10.57 Mn
Sep 30, 2022 -10.42 Mn
Jun 30, 2022 -2.70 Mn
Mar 31, 2022 -2.26 Mn
Dec 31, 2021 2.35 Mn
Sep 30, 2021 55.84 Mn
Jun 30, 2021 -29.66 Mn